Charles S. Berkman
2017 - Ligand Pharmaceuticals
In 2017, Charles S. Berkman earned a total compensation of $1.5M as Senior Vice President and General Counsel at Ligand Pharmaceuticals, a 15% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $174,150 |
|---|---|
| Option Awards | $486,593 |
| Salary | $362,812 |
| Stock Awards | $466,461 |
| Other | $8,803 |
| Total | $1,498,819 |
Berkman received $486.6K in option awards, accounting for 32% of the total pay in 2017.
Berkman also received $174.2K in non-equity incentive plan, $362.8K in salary, $466.5K in stock awards and $8.8K in other compensation.
Rankings
In 2017, Charles S. Berkman's compensation ranked 6,989th out of 14,666 executives tracked by ExecPay. In other words, Berkman earned more than 52.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,989 out of 14,666 | 52nd |
Division Manufacturing | 2,592 out of 5,772 | 55th |
Major group Chemicals And Allied Products | 841 out of 2,075 | 60th |
Industry group Drugs | 654 out of 1,731 | 62nd |
Industry Pharmaceutical Preparations | 513 out of 1,333 | 62nd |
Source: SEC filing on April 30, 2018.
Berkman's colleagues
We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2017.